Zofin

DRUG4 trials

Sponsors

ZEO ScientifiX, Inc.

Conditions

Acute Respiratory Distress SyndromeCOPDCOVID-19Corona Virus InfectionCovid19SARSSARS (Severe Acute Respiratory Syndrome)

Phase 1

Zofin (Organicell Flow) for Patients With COVID-19

CompletedNCT04384445

ZEO ScientifiX, Inc.Acute Respiratory Distress Syndrome, Corona Virus Infection, COVID-19 +1

Start: 2020-09-08End: 2023-07-01Updated: 2023-11-01

Zofin to Treat COVID-19 Long Haulers

CompletedNCT05228899

ZEO ScientifiX, Inc.COVID-19

Start: 2022-04-14End: 2023-10-18Updated: 2023-11-01

Zofin to Treat Chronic Obstructive Pulmonary Disease (COPD)

SuspendedNCT05643729

ZEO ScientifiX, Inc.COPD

Start: 2023-11-15End: 2024-08-31Target: 20Updated: 2023-11-01

Unknown Phase

Expanded Access to Zofin for Patients With COVID-19

ZEO ScientifiX, Inc.Acute Respiratory Distress Syndrome, Corona Virus Infection, Covid19 +1

Updated: 2023-03-23

Related Papers

STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: A structured protocol

PLoS ONE2023-02-1529 citations